Loading
Life sciences · Journal article
Expert Opinion on Therapeutic Targets · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
INTRODUCTION: There is currently growing interest in targeting senescent tumor cells as a strategy for improving the efficacy of cancer therapy. Despite the promise of this strategy, a number of limitations have emerged relating to the utility of senescence-eliminating agents, collectively termed senolytics. First, these compounds show different outcomes in aging and tumor cell models. Second, they exhibit variable efficacy in eliminating senescent tumor cells based on tumor background. Third, efficacious agents do not necessarily eliminate the risk of proliferative recovery that could reflect disease recurrence. Fourth, several of the compounds that demonstrate the highest efficacy against senescent tumor cells are associated with established or potential adverse effects that would limit their translation. AREAS COVERED: Here, we provide an overview of the advantages and disadvantages of established senolytics and explore the potential for newly identified agents strictly tested in tumor cell models. EXPERT OPINION: Senolytic translation is constrained by TIS heterogeneity generating resistant subpopulations, potential proliferative recovery, senolytic-associated adverse effects, inability to spare beneficial senescent cells, and absence of validated clinical trial designs. Emerging immune-based strategies nanovaccines, nano-antigen-presenting machinery, and CAR-T platforms offer more selective alternatives, but require validated preclinical and clinical testing for further implementation.